NCT07332533 2026-01-12
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
Clinical Trials
11 trialsNCT07251062 2025-11-26
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2/3 Not yet recruiting
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT03414983 2023-11-18
CheckMate 9X8
Bristol-Myers Squibb
Phase 2/3 Completed
NCT04037241 2022-04-01
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
Sorrento Therapeutics, Inc.
Phase 2/3 Withdrawn
NCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT00735241 2015-05-22
FAST
Sirtex Medical
Phase 2/3 Withdrawn
NCT00284258 2012-11-02
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2/3 Completed
NCT00261703 2012-05-11
Docetaxel in Head and Neck Cancer
Sanofi
Phase 2/3 Completed
NCT00401323 2011-01-20
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Phase 2/3 Completed